References New England Journal of Medicine - Retatrutide Phase 2 Trial - Primary efficacy and safety data for retatrutide New England Journal of Medicine - SURMOUNT-1 Trial - Tirzepatide obesity trial results FDA - Zepbound (Tirzepatide) Approval - FDA approval information for tirzepatide ClinicalTrials.gov - Retatrutide Studies - Ongoing Phase 3 clinical trials ClinicalTrials.gov - Retatrutide Phase 3 trials Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice
Wipe the top of the sermorelin vial with an alcohol prep pad
Patients with obesity typically have difficulty with mobility and energy levels, which can contribute to their struggle to lose weight
Over the past three to five years, Ozempic, Wegovy, and Rybelsus have gained substantial popularity
Rather than following traditional dosing protocols, patients and physicians are exploring whether smaller amounts can still provide meaningful benefits while minimizing potential side effects
Managing side effects While both medications can cause nausea, vomiting, and gastrointestinal discomfort, some people find that one is more tolerable than the other
